Alnylam is certainly developing ALN-TTR.

ALN-TTR targets a region of the gene common to wild-type and all known mutant types of TTR, and as a result, has potential as a therapeutic for all individuals with FAC and FAP.D., Vice President, Research, Oncology and CNS at Alnylam. These data offer continued validation of our RNAi therapeutics technique, and we are looking forward to advancing the program towards the clinic.D., Professor of Biochemistry, Molecular Neurobiology Group, Institute for Molecular and Cellular Biology in Portugal. ALN-TTR has been advanced using stable nucleic acid-lipid particles delivery technology in collaboration with Tekmira Pharmaceuticals Corporation.. Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program Alnylam Pharmaceuticals, Inc.

Results Patients A total of 2218 patients were signed up for the trial from 65 sites in nine Europe from March 10, 2013, through June 20, 2013 . Of these individuals, 1102 were randomly designated to the bivalirudin group and 1116 to the control group with optional receipt of a glycoprotein IIb/IIIa inhibitor. Of the 2218 individuals who provided preliminary abridged informed consent, 2198 provided formal written educated consent ; these patients were included in the intention-to-treat populace. The baseline features of patients were generally well matched between your two groups, although there were higher rates of diabetes and previous myocardial infarction in the control group .Results Patients A total of 2218 patients were signed up for the trial from 65 sites in nine Europe from March 10, 2013, through June 20, 2013 . Of these individuals, 1102 were randomly designated to the bivalirudin group and 1116 to the control group with optional receipt of a glycoprotein IIb/IIIa inhibitor. Of the 2218 individuals who provided preliminary abridged informed consent, 2198 provided formal written educated consent ; these patients were included in the intention-to-treat populace. The baseline features of patients were generally well matched between your two groups, although there were higher rates of diabetes and previous myocardial infarction in the control group .